课题基金 / 基金详情

Engineering next-generation self-amplifying RNA therapeutics encoding bispecific T cell engager (BiTE) antibodies for treatment of ovarian cancer

Engineering next-generation self-amplifying RNA therapeutics encoding bispecific T cell engager (BiTE) antibodies for treatment of ovarian cancer
工程编码双特异性 T 细胞接合器 (BiTE) 抗体的下一代自扩增 RNA 疗法用于治疗卵巢癌
批准号:
478813
负责人:
Blakney Anna
金额:
$57.96万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2023
资助国家:
加拿大
项目状态:
未结题
起止时间:
2023-03-01 至 2028-03-01

项目摘要

项目成果

Blakney Anna的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Ovarian cancer is the most fatal gynecological cancer in Canada, largely due to the lack of effective treatments. Recently, a novel type of antibody approach called a Bi-specific T Cell Engager (BiTE) has shown promising preclinical efficacy for treating
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of next-generation RNA vaccines for pandemic preparedness
  • 批准号:
    473356
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    Blakney Anna
  • 依托单位:
Canada Research Chairs - Tier 2
  • 批准号:
    480977
  • 项目类别:
  • 资助金额:
    $43.71万
  • 财政年份:
    2022
  • 负责人:
    Blakney Anna
  • 依托单位:
Characterization of first- and second-generation RNA vaccine immunogenicity against SARS-CoV-2 variants of concern in Canada
  • 批准号:
    459284
  • 项目类别:
    Operating Grants
  • 资助金额:
    $18.07万
  • 财政年份:
    2021
  • 负责人:
    Blakney Anna
  • 依托单位:
Mechanisms of immunity and protection against Chlamydia of RNA and protein vaccines
  • 批准号:
    453433
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2021
  • 负责人:
    Blakney Anna
  • 依托单位:
海外基金